COMPANY

Lyell Immunopharma

HQ: South San Francisco, CA source · lyell.com ↗ · West Coast

We own and operate the LyFE Manufacturing Center™ in Bothell, Washington. From company website Source · Oct 13, 2026

Keywords: oncology cancer refractory metastatic colorectal cancer Non-small Cell Lung Cancer Recurrent NSCLC Relapsed Non-Hodgkin Lymphoma Refractory Non-Hodgkin Lymphoma Non-Hodgkin Lymphoma Large B-cell Lymphoma Triple Negative Breast Cancer Non Small Cell Lung Cancer Metastatic Advanced Breast Cancer Advanced Lung Carcinoma NSCLC NSCLC Stage IV Relapse/Recurrence Recurrent Breast Cancer Platinum-resistant Ovarian Cancer Ovarian Cancer Primary Peritoneal Carcinoma Fallopian Tube Cancer Endometrial Cancer Endometrioid Tumor High Grade Serous Carcinoma Ovarian Epithelial Cancer B-Cell Lymphoma Non-Hodgkin Lymphoma Refractory/ Relapsed Diffuse Large B Cell Lymphoma Diffuse Large B Cell Lymphoma Refractory Diffuse Large B Cell Lymphoma Relapsed TNBC - Triple-Negative Breast Cancer Melanoma Systemic Lupus Erythematosus Lupus Nephritis IMPT-514 LYL273 LYL797 LYL845

Location: South San Francisco, CA · source · Oct 15, 2026

Profile checked Oct 10, 2026

$200.0MRaised (2 yrs)7Trials (company is sponsor)

Timeline

Mar 9, 2026 Raise Private placement: $50M (total, as published), announced Mar 9, 2026. Source: company release on GlobeNewswire. source ↗
Jan 12, 2026 Trial start Phase 3: A Study to Investigate Ronde-cel Versus Investigator's Choice CD19 CAR T-Cell Therapy source ↗
Jul 25, 2025 Raise Private placement: $50M (initial closing, as published); deal value up to $100M (not counted as received), announced Jul 25, 2025. Source: SEC filing. source ↗
Jul 25, 2025 Raise Private placement: $100M (total, as published), announced Jul 25, 2025. Source: company release on GlobeNewswire. source ↗
Feb 15, 2024 Trial start Phase 1/Phase 2: A Study of IMPT-514 in Active Refractory Lupus Nephritis (LN) and Systemic Lupus Erythematosus (SLE) source ↗
May 19, 2023 Trial start —: A Biomarker Screening Protocol for Participants With Solid Tumors source ↗
May 9, 2023 Trial start Phase 1/Phase 2: Study of Rondecabtagene Autoleucel in Aggressive Large B-Cell Lymphoma source ↗
Dec 19, 2022 Trial start Phase 1: A Study to Investigate LYL845 in Adults With Solid Tumors source ↗
Aug 1, 2022 Trial start Phase 1/Phase 2: LYL273 for Patients With Relapsed or Refractory mCRC source ↗
Mar 29, 2022 Trial start Phase 1: A Study to Investigate LYL797 in Adults With Solid Tumors source ↗

Upcoming milestones

2028-06 (ESTIMATED) · Phase 1/Phase 2 · LYL273 for Patients With Relapsed or Refractory mCRC · NCT05319314
Dec 31, 2028 (ESTIMATED) · Phase 1/Phase 2 · Study of Rondecabtagene Autoleucel in Aggressive Large B-Cell Lymphoma · NCT05826535
2029-12 (ESTIMATED) · Phase 3 · A Study to Investigate Ronde-cel Versus Investigator's Choice CD19 CAR T-Cell Therapy · NCT07188558

Estimated primary completion per ClinicalTrials.gov. Dates move.

Funding

Raised: $200.0M. Last 2 years.

Mar 9, 2026 Private placement: $50M (total, as published), announced Mar 9, 2026. Source: company release on GlobeNewswire. source ↗
Jul 25, 2025 Private placement: $50M (initial closing, as published); deal value up to $100M (not counted as received), announced Jul 25, 2025. Source: SEC filing. source ↗
Jul 25, 2025 Private placement: $100M (total, as published), announced Jul 25, 2025. Source: company release on GlobeNewswire. source ↗

Clinical trials (lead sponsor) 7

Record	Title	Phase	Status	Start	Primary completion
NCT05826535	Study of Rondecabtagene Autoleucel in Aggressive Large B-Cell Lymphoma	Phase 1/Phase 2	Recruiting	May 9, 2023	Dec 31, 2028 (estimated)
NCT07188558	A Study to Investigate Ronde-cel Versus Investigator's Choice CD19 CAR T-Cell Therapy	Phase 3	Recruiting	Jan 12, 2026	2029-12 (estimated)
NCT05319314	LYL273 for Patients With Relapsed or Refractory mCRC	Phase 1/Phase 2	Recruiting	Aug 1, 2022	2028-06 (estimated)
NCT05274451	A Study to Investigate LYL797 in Adults With Solid Tumors	Phase 1	Terminated	Mar 29, 2022	Nov 27, 2024 (actual)
NCT05573035	A Study to Investigate LYL845 in Adults With Solid Tumors	Phase 1	Terminated	Dec 19, 2022	Jan 9, 2025 (actual)
NCT05891197	A Biomarker Screening Protocol for Participants With Solid Tumors	Not listed	Terminated	May 19, 2023	Feb 5, 2025 (actual)
NCT06153095	A Study of IMPT-514 in Active Refractory Lupus Nephritis (LN) and Systemic Lupus Erythematosus (SLE)	Phase 1/Phase 2	Withdrawn	Feb 15, 2024	Jan 9, 2025 (actual)